This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Catargi, B. Articles by Tabarin, A. Search for Related Content PubMed PubMed Citation Articles by Catargi, B. Articles by Tabarin, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cushing's Syndrome Diabetes Hazardous Substances DB DEXAMETHASONE HYDROCORTISONE

Occult Cushing’s Syndrome in Type-2 Diabetes

Departments of Endocrinology (B.C., A.P., V.B., N.R.-C., P.R., A.T.) and Nutrition (V.R., V.V., H.G.), Institut de Recherche en Nutrition Humaine en Aquitaine, University Hospital of Bordeaux, 33604 Pessac, France

Address all correspondence and requests for reprints to: Antoine Tabarin, Department of Endocrinology, University Hospital of Bordeaux, Avenue de Magellan, 33604 Pessac, France. E-mail: antoine.tabarin{at}chu-bordeaux.fr.

Subclinical Cushing’s syndrome (SCS) caused by adrenal incidentalomas is frequently associated with overweight and insulin resistance. Metabolic syndrome X may therefore be a clue to the presence of CS. However, the incidence of CS in this situation remains unknown. We have conducted a prospective study to evaluate the prevalence of occult CS in overweight, type-2 diabetic patients devoided of specific clinical symptoms of CS.

Two hundred overweight, type-2 diabetic patients, consecutively referred for poor metabolic control (HbA_1C > 8%), were studied as inpatients. A first screening step was performed with the 1-mg overnight dexamethasone suppression test (DST) using a revised criterion for cortisol suppression (60 nmol/liter) to maximize the sensitivity of the procedure. A second confirmatory step of biochemical investigations (midnight plasma cortisol concentration, plasma cortisol circadian rhythm, morning plasma ACTH concentration, 24-h urinary free cortisol, and 4-mg iv DST) was performed in patients with impaired 1-mg DST. A third step of imaging studies was performed according to the results of second-step investigations.

Fifty-two patients had impaired 1-mg DST. Among these, 47 were further evaluated. Thirty were considered as false positives of the 1-mg DST, whereas 17 displayed at least one additional biological abnormality of the hypothalamic-pituitary-adrenal axis. Definitive occult CS was identified in four patients (2% of the whole series) with Cushing’s disease (n = 3) and surgically proven adrenal adenoma (n = 1). Definitive diagnosis remains to be established in seven additional patients (3.5%) with mild occult CS associated with unsuppressed plasma ACTH concentrations and a unilateral adrenal tumor of 10–29 mm in size showing prevalent uptake at radiocholesterol scintigraphy.

In conclusion, a relatively high prevalence of occult CS was found in our study. Further studies are needed to evaluate the impact of the cure of occult CS on obesity and diabetes mellitus in these patients. Such studies might provide a rationale for systematic screening of occult CS in this population.

Abbreviations: BMI, Body mass index; CD, Cushing’s disease; CS, Cushing’s syndrome; CT, computed tomography; DM, diabetes mellitus; DST, dexamethasone suppression test; HbA1c, glycosylated hemoglobin; HPA, hypothalamic-pituitary-adrenal; SCS, subclinical Cushing’s syndrome; UFC, urinary free cortisol; WHR, waist-to-hip ratio.

This article has been cited by other articles:

				S. K. Baid, D. Rubino, N. Sinaii, S. Ramsey, A. Frank, and L. K. Nieman Specificity of Screening Tests for Cushing's Syndrome in an Overweight and Obese Population J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3857 - 3864. [Abstract] [Full Text] [PDF]

				M. Boscaro and G. Arnaldi Approach to the Patient with Possible Cushing's Syndrome J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3121 - 3131. [Abstract] [Full Text] [PDF]

				C. Fagour, S. Bardet, V. Rohmer, Y. Arimone, P. Lecomte, N. Valli, and A. Tabarin Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study Eur. J. Endocrinol., February 1, 2009; 160(2): 257 - 264. [Abstract] [Full Text] [PDF]

				M.-L. Nunes, S. Vattaut, J.-B. Corcuff, A. Rault, H. Loiseau, B. Gatta, N. Valli, L. Letenneur, and A. Tabarin Late-Night Salivary Cortisol for Diagnosis of Overt and Subclinical Cushing's Syndrome in Hospitalized and Ambulatory Patients J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 456 - 462. [Abstract] [Full Text] [PDF]

				G. Reimondo, S. Bovio, B. Allasino, S. De Francia, B. Zaggia, I. Micossi, A. Termine, F. De Martino, P. Paccotti, F. Di Carlo, et al. The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome Eur. J. Endocrinol., November 1, 2008; 159(5): 569 - 576. [Abstract] [Full Text] [PDF]

				L. K. Nieman, B. M. K. Biller, J. W. Findling, J. Newell-Price, M. O. Savage, P. M. Stewart, and V. M. Montori The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1526 - 1540. [Abstract] [Full Text] [PDF]

				M. B. Elamin, M. H. Murad, R. Mullan, D. Erickson, K. Harris, S. Nadeem, R. Ennis, P. J. Erwin, and V. M. Montori Accuracy of Diagnostic Tests for Cushing's Syndrome: A Systematic Review and Metaanalyses J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1553 - 1562. [Abstract] [Full Text] [PDF]

				S. Kidambi, H. Raff, and J. W Findling Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome Eur. J. Endocrinol., December 1, 2007; 157(6): 725 - 731. [Abstract] [Full Text] [PDF]

				I. Chiodini, M. L. Mascia, S. Muscarella, C. Battista, S. Minisola, M. Arosio, S. A. Santini, G. Guglielmi, V. Carnevale, and A. Scillitani Subclinical Hypercortisolism among Outpatients Referred for Osteoporosis Ann Intern Med, October 16, 2007; 147(8): 541 - 548. [Abstract] [Full Text] [PDF]

				L. K. Nieman Screening for Reversible Osteoporosis: Is Cortisol a Culprit? Ann Intern Med, October 16, 2007; 147(8): 582 - 584. [Full Text] [PDF]

				H. Bruehl, M. Rueger, I. Dziobek, V. Sweat, A. Tirsi, E. Javier, A. Arentoft, O. T. Wolf, and A. Convit Hypothalamic-Pituitary-Adrenal Axis Dysregulation and Memory Impairments in Type 2 Diabetes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2439 - 2445. [Abstract] [Full Text] [PDF]

				J. W. Findling and H. Raff Cushing's Syndrome: Important Issues in Diagnosis and Management J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3746 - 3753. [Abstract] [Full Text] [PDF]

				D. Zelena, L. Filaretova, Z. Mergl, I. Barna, Z. E. Toth, and G. B. Makara Hypothalamic paraventricular nucleus, but not vasopressin, participates in chronic hyperactivity of the HPA axis in diabetic rats Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E243 - E250. [Abstract] [Full Text] [PDF]

				I. Chiodini, M. Torlontano, A. Scillitani, M. Arosio, S. Bacci, S. Di Lembo, P. Epaminonda, G. Augello, R. Enrini, B. Ambrosi, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients Eur. J. Endocrinol., December 1, 2005; 153(6): 837 - 844. [Abstract] [Full Text] [PDF]